TIDMFUM
RNS Number : 5668Z
Futura Medical PLC
15 January 2024
15 January 2024
Futura Medical plc
("Futura" or the "Company")
Futura Medical extends collaboration with Cooper Consumer
Health
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the
pharmaceutical company developing innovative sexual health products
, today announces that it has extended until January 2029 its
exclusive licensing agreement with Cooper Consumer Health
("Cooper"), a leading European independent self-care organisation,
for the rights to commercialise Eroxon (R), the Company's topical,
gel-based Erectile Dysfunction ("ED") treatment, throughout the
European Economic Area, United Kingdom and Switzerland.
The extension builds on an initial agreement signed in May 2022
for the exclusive rights to commercialise Eroxon in these
territories for an initial five-year period. The terms of the
agreement are otherwise unchanged with Futura remaining the Legal
Manufacturer(1) and responsible for the supply of Eroxon through
its third-party contract manufacturers. Futura looks forward to
continuing to grow its relationship with Cooper.
Eroxon has been approved as the first pan-European topical
treatment for ED available without prescription. Initial launches
commenced in March 2023 in the UK and Belgium, with further
launches across Europe during 2024, including the key markets of
Italy, Spain, France and Germany.
James Barder, Chief Executive Officer of Futura Medical said :
"The award-winning launch of Eroxon was a key milestone in our
partnership with Cooper and the success of our collaboration makes
this extension an easy decision for both parties. We are committed
to providing treatment to those suffering from ED and as such we
continue the commercial roll-out of Eroxon across the world."
Bart Meermans, President of Cooper Consumer Health said:
"Cooper's ambition is to become a leading European consumer
healthcare platform. Eroxon is an exciting new innovation for the
erectile dysfunction market and we look forward to working closely
with Futura with the continuing launches of Eroxon across our
markets."
(1) Legal manufacturer means the organisation responsible for
the design, manufacture, packaging and labelling of a device before
it is placed on the market under that organisation's own name,
regardless of whether these operations are carried out by that
organisation or on its behalf by a third party contract
manufacturer.
ENDS
For further information please contact:
Futura Medical plc
James Barder, Chief Executive Officer
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Nick Bastin / Jonathan Edwards / Elena Bates
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative sexual health products based
on its proprietary, transdermal DermaSys(R) technology. Each
DermaSys(R) formulation is separately patented and specifically
tailored for the selected indication and application, as well as
being optimised for clinical efficacy, safety, administration and
patient convenience. The products are developed for the
prescription and consumer healthcare markets as appropriate.
Development and commercialisation strategies are designed to
maximise product differentiation and value creation whilst
minimising risk.
MED3000 is Futura's topical gel formulation that is a novel
treatment for erectile dysfunction ("ED") through a unique
evaporative mode of action and is sold in Europe and the UK under
the brand name Eroxon(R). Futura has conducted two Phase 3 studies
using MED3000 in ED; the FM57 study which enabled Futura to be
granted a CE Mark in 2021 and FM71 which enabled Futura to be
granted US marketing authorisation. Both studies demonstrated that
MED3000 presents an effective clinically proven treatment for ED
with a rapid speed of onset and a favourable benefit versus risk
profile ideally suited for an 'Over the Counter'
classification.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
About Cooper Consumer Health Group
Cooper Consumer Health Group ("Cooper") is the largest
independent selfcare organization in Europe that is active in the
OTC consumer healthcare market with the development, manufacturing,
selling and marketing of selfcare products (e.g. medicines, medical
devices, cosmetics, biocides and food supplements) under its own or
licensed brands.
The ambition of the group is to offer selfcare solutions to
everyone based on a European brands portfolio. Cooper has proven
its capacity to integrate new activities and aggregate talents by
capitalising on the
strengths and the structure of its group. www.cooperconsumerhealth.eu
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBBGDBXGBDGSD
(END) Dow Jones Newswires
January 15, 2024 02:00 ET (07:00 GMT)
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
